Kết quả tìm kiếm - Larry D. Anderson

Tinh chỉnh kết quả
  1. 1
    Continued Refinement of the Treatment for Light-Chain Cardiac Amyloidosis

    Continued Refinement of the Treatment for Light-Chain Cardiac Amyloidosis Bằng Justin L. Grodin, Larry D. Anderson, Ankit Kansagra

    Được phát hành 2021
    lấy văn bản lấy văn bản
    Carta
    Lưu vào danh sách
    Đã lưu trong:
  2. 2
    Toxicity of CAR T-Cell Therapy for Multiple Myeloma

    Toxicity of CAR T-Cell Therapy for Multiple Myeloma Bằng Aimaz Afrough, Pearl Abraham, Laura Turer, Gurbakhash Kaur, Aishwarya Sannareddy, Doris K. Hansen, Larry D. Anderson

    Được phát hành 2024
    lấy văn bản
    Revisão
    Lưu vào danh sách
    Đã lưu trong:
  3. 3
    DNA Immunization Against Amyloid beta 42 has High Potential as Safe Therapy for Alzheimer’s Disease as it Diminishes Antigen-Specific Th1 and Th17 Cell Proliferation

    DNA Immunization Against Amyloid beta 42 has High Potential as Safe Therapy for Alzheimer’s Disease as it Diminishes Antigen-Specific Th1 and Th17 Cell Proliferation Bằng Doris Lambracht‐Washington, Bao Xi Qu, Min Fu, Larry D. Anderson, Olaf Stüve, Todd N. Eagar, Roger N. Rosenberg

    Được phát hành 2011
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  4. 4
    Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

    Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantat... Bằng Miguel‐Angel Perales, Larry D. Anderson, Tania Jain, Saad S. Kenderian, Olalekan O. Oluwole, Gunjan L. Shah, Jakub Svoboda, Mehdi Hamadani

    Được phát hành 2022
    lấy văn bản
    Revisão
    Lưu vào danh sách
    Đã lưu trong:
  5. 5
    Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

    Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Pane... Bằng Larry D. Anderson, Binod Dhakal, Tania Jain, Olalekan O. Oluwole, Gunjan L. Shah, Surbhi Sidana, Miguel‐Angel Perales, Marcelo C. Pasquini

    Được phát hành 2023
    lấy văn bản
    Revisão
    Lưu vào danh sách
    Đã lưu trong:
  6. 6
    Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis

    Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis Bằng Fieke W. Hoff, Rahul Banerjee, Adeel Khan, Georgia McCaughan, Bo Wang, Xiaoliang Wang, James Roose, Larry D. Anderson, Andrew J. Cowan, S. Vincent Rajkumar, Gurbakhash Kaur

    Được phát hành 2024
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  7. 7
    Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma

    Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma Bằng Shaji Kumar, Rachid Baz, Robert Z. Orlowski, Larry D. Anderson, Hong Ma, Alexandria M Shrewsbury, Katrina Croghan, Mrinalini Bilgi, Ankit Kansagra, Prashant Kapoor, Zonghai Li, Jason Brayer

    Được phát hành 2020
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  8. 8
    Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis

    Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis Bằng Sharlene Dong, Rahul Banerjee, Adeel Khan, Mengru Wang, Xiaoliang Wang, Anosheh Afghahi, Aimaz Afrough, Murali Janakiram, Bo Wang, Andrew J. Cowan, Adam S. Sperling, Larry D. Anderson, S. Vincent Rajkumar, Gurbakhash Kaur

    Được phát hành 2025
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  9. 9
    Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

    Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma Bằng Danai Dima, James A. Davis, Nausheen Ahmed, Aishwarya Sannareddy, Hira Shaikh, Zahra Mahmoudjafari, Jack Khouri, Gurbakhash Kaur, Christopher Strouse, Jason Valent, Larry D. Anderson, Faiz Anwer, Al‐Ola Abdallah, Hamza Hashmi

    Được phát hành 2023
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  10. 10
    Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

    Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy Bằng Olalekan O. Oluwole, Bhagirathbhai Dholaria, Tristan Knight, Tania Jain, Frederick L. Locke, Linda Ramsdell, Sarah Nikiforow, Hamza Hashmi, Kathy Mooney, Shakthi Bhaskar, Katrina Morris, Katie S. Gatwood, Brittney Baer, Larry D. Anderson, Mehdi Hamadani

    Được phát hành 2023
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  11. 11
    Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent

    Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent Bằng Benjamin A. Derman, Ankit Kansagra, Jeffrey A. Zonder, Andrew Stefka, David L. Grinblatt, Larry D. Anderson, Sandeep Gurbuxani, Sunil Narula, Shayan Rayani, Ajay Major, Andrew Kin, Ken Jiang, Theodore Karrison, Jagoda Jasielec, Andrzej Jakubowiak

    Được phát hành 2022
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  12. 12
    Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study

    Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with... Bằng Susan Bal, Mehmet H. Kocoglu, Omar Nadeem, Myo Htut, Tara Gregory, Larry D. Anderson, Luciano J. Costa, Tonia J. Buchholz, Safiyyah Ziyad, Meng Li, Yanping Chen, Allison Kaeding, Michael R. Burgess, Kristen Hege, Jesús G. Berdeja

    Được phát hành 2022
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  13. 13
    KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

    KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma Bằng Sundar Jagannath, Yi Lin, Hartmut Goldschmidt, Donna Reece, Ajay K. Nooka, Alicia Senín, Paula Rodríguez‐Otero, R Powles, Kosei Matsue, Nina Shah, Larry D. Anderson, Matthew Streetly, Kimberly Wilson, Hoa Le, Arlene S. Swern, Amit Agarwal, David S. Siegel

    Được phát hành 2021
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  14. 14
    Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

    Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel Bằng Bruno Paiva, Irene Manrique, Julie Rytlewski, Timothy Campbell, Christian C. Kazanecki, Nathan Martin, Larry D. Anderson, Jesús G. Berdeja, Sagar Lonial, Noopur Raje, Yi Lin, Philippe Moreau, Jesús F. San Miguel, Nikhil C. Munshi, Shari M. Kaiser

    Được phát hành 2023
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  15. 15
    Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial

    Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial Bằng Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, Peter M. Voorhees, Brandi Reeves, Edward N. Libby, Paul G. Richardson, Larry D. Anderson, Heather J. Sutherland, Kwee Yong, Axel Hoos, M Gorczyca, Soumi Lahiri, Zangdong He, Daren Austin, Joanna Opalinska, Adam D. Cohen

    Được phát hành 2018
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  16. 16
    Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

    Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse Bằng Meletios Α. Dimopoulos, Katja Weisel, Philippe Moreau, Larry D. Anderson, Darrell White, Jesús F. San Miguel, Pieter Sonneveld, Monika Engelhardt, Matthew Jenner, Alessandro Corso, Jan Dürig, Michel Pavic, Morten Salomo, Eva Casal, Shankar Srinivasan, Xin Yu, Tuong Vi Nguyen, Tsvetan Biyukov, Teresa Peluso, Paul G. Richardson

    Được phát hành 2020
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  17. 17
    BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

    BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myelo... Bằng Susan Bal, Myo Htut, Omar Nadeem, Larry D. Anderson, Hakan Koçoğlu, Tara Gregory, Adriana Rossi, Tom Martin, Daniel Egan, Luciano J. Costa, Hongxiang Hu, Yanping Chen, Shaoyi Li, Lisa M. Kelly, Naomey Sarkis, Safiyyah Ziyad, Wei-Ming Kao, Allison Kaeding, Michael R. Burgess, Jesús G. Berdeja

    Được phát hành 2023
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  18. 18
    Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

    Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study Bằng Ashraf Badros, Laahn Foster, Larry D. Anderson, Chakra P Chaulagain, Erin M. Pettijohn, Andrew J. Cowan, Caitlin Costello, Sarah Larson, Douglas W. Sborov, Kenneth H. Shain, Rebecca Silbermann, Nina Shah, Alfred Chung, Maria Krevvata, Huiling Pei, Sharmila Patel, Vipin Khare, Annelore Cortoos, Robin Carson, Thomas S. Lin, Peter M. Voorhees

    Được phát hành 2024
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  19. 19
    Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

    Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Bằng Surbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, Michael Heim, Ruta Brazauskas, Doris K. Hansen, Christopher Ferreri, Ciara L. Freeman, Aimaz Afrough, Larry D. Anderson, Binod Dhakal, Devender Dhanda, Lohith Gowda, Hamza Hashmi, Melanie Harrison, Amani Kitali, Abu‐Sayeef Mirza, Jinalben Patel, Pallavi Patwardhan, Saad Z. Usmani, Krina K. Patel, Siddhartha Ganguly, Marcelo C. Pasquini

    Được phát hành 2023
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  20. 20
    Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis

    Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis Bằng Surbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, Ruta Brazauskas, Temitope Oloyede, Matthew Bye, Doris K. Hansen, Christopher Ferreri, Ciara L. Freeman, Aimaz Afrough, Larry D. Anderson, Binod Dhakal, Devender Dhanda, Lohith Gowda, Hamza Hashmi, Melanie J. Harrison, Amani Kitali, Heather Landau, Abu‐Sayeef Mirza, Pallavi Patwardhan, Muzaffar H. Qazilbash, Saad Z. Usmani, Krina K. Patel, Taiga Nishihori, Siddhartha Ganguly, Marcelo C. Pasquini

    Được phát hành 2025
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:

Công cụ tìm kiếm: